Table 3 Multivariate analysis results

Acute GVHD (grades 2–4)^a

 Non-rituximab RIC

1004

1

0.43

 Rituximab-containing RIC

377

1.14

0.83

1.56

Acute GVHD (grades 3–4)^a

 Non-rituximab RIC

1004

1

0.54

 Rituximab-containing RIC

377

1.16

0.72

1.89

Chronic GVHD

 Non-rituximab RIC

982

1

0.22

 Rituximab-containing RIC

369

1.15

0.92

1.46

Non-relapse mortality

 Non-rituximab RIC

988

1

0.51

 Rituximab-containing RIC

367

0.90

0.67

1.22

Progression/relapse

 Non-rituximab RIC

988

1

0.055

 Rituximab-containing RIC

367

0.79

0.63

1.01

PFS

 Non-rituximab RIC

988

1

0.006

 Rituximab-containing RIC

367

0.76

0.62

0.92

Mortality

 Non-rituximab RIC

1022

1

0.08

 Rituximab-containing RIC

379

0.84

0.69

1.02